Trial Profile
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Sponsors Sun Pharmaceutical Industries
- 13 Sep 2020 Status changed to discontinued.
- 04 Oct 2019 Status changed from recruiting to completed.
- 02 Nov 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.